Faculty of Health Sciences, University of Sydney, Lidcombe, NSW, Australia.
Breast Cancer Res Treat. 2010 Apr;120(3):649-54. doi: 10.1007/s10549-010-0793-3. Epub 2010 Feb 24.
To assess the impact of air travel on swelling of the 'at risk' arm of women treated for breast cancer. Women treated for breast cancer from Canada (n = 60) and from within Australia (n = 12) attending a dragon boat regatta in Queensland, Australia participated. Women were measured within 2 weeks prior to their flight, on arrival in Queensland and, for 40 women travelling from Canada, measured again 6 weeks following return to Canada. Changes to extracellular fluid were measured using a single-frequency bioimpedance device (BIA). Each arm was measured separately using a standardized protocol to obtain the inter-limb impedance ratio. An increase in the ratio indicates accumulated fluid. Information regarding medical management of participants' breast cancer, use of compression garment and history of exercise were also obtained. For most women (95%), air travel did not adversely affect the impedance ratio. The BIA ratio of long-haul travellers was 1.007 +/- 0.065 prior to the flight and 1.006 +/- 0.087 following the flight. The ratio of short-haul travellers was 0.994 +/- 0.033 and following the flight was 1.001 +/- 0.038. Air travel did not cause significant change in BIA ratio in the 'at-risk' arm for the majority of breast cancer survivors who participated in dragon boat racing. Further research is required to determine whether these findings are generalizable to the population of women who have been treated for breast cancer.
评估航空旅行对接受乳腺癌治疗的女性“风险”手臂肿胀的影响。参加澳大利亚昆士兰州龙舟赛的来自加拿大(n = 60)和澳大利亚(n = 12)的乳腺癌治疗女性参与了此项研究。在飞行前 2 周内、抵达昆士兰时以及对于从加拿大旅行的 40 名女性,在返回加拿大 6 周后再次进行测量。使用单频生物阻抗设备(BIA)测量细胞外液的变化。使用标准化协议分别测量每个手臂,以获得肢体间阻抗比。比值的增加表明有流体积累。还获得了有关参与者乳腺癌的医疗管理、压缩服的使用和运动史的信息。对于大多数女性(95%),航空旅行不会对阻抗比产生不利影响。长途旅行者的 BIA 比值在飞行前为 1.007 +/- 0.065,飞行后为 1.006 +/- 0.087。短途旅行者的比值为 0.994 +/- 0.033,飞行后为 1.001 +/- 0.038。航空旅行在大多数参加龙舟赛的乳腺癌幸存者的“风险”手臂中没有引起 BIA 比值的显著变化。需要进一步的研究来确定这些发现是否适用于接受过乳腺癌治疗的女性人群。